Similarly, neuraminidase-inhibitors have shown therapeutic promise, as suppression of NEU3 has been found to inhibit the invasion of aggressive bladder cancer cells, positioning NEU3 as a potential target for treating refractory bladder cancer [55]. This evidence concerns the gene NEU3 and urinary bladder cancer.